Optimizing T Cell Priming Using TLR4/9 Combination Adjuvant For Robust Cell-Mediated Immunity Against Influenza 2307646
Subunit vaccines are safe but rarely induce robust, long-lasting immunity, especially cell-mediated immunity (CMI). Here, we investigated the potential of IVAX-1, a combination of TLR4 (MPLA) and TLR9 (CpG 1018) agonists formulated in a squalene oil-in-water emulsion (AddaVax), to mediate protection and generate...